GlassScriptPhysician profile
Josephine Vu
NPI 1790256436
$12,829.24
in general payments reported to CMS, 2019-2025
47 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,369 · 2022: $2,228 · 2023: $2,449 · 2024: $3,424 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,062 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,061.51 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,585.38 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $1,215.22 | 2021-2025 | Tepezza, Evenity, Repatha |
| Novo Nordisk INC | $913.88 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Insulet Corporation | $772.49 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $690.63 | 2021-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $541.01 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Recordati_rare_diseases_inc. | $470.40 | 2023-2025 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals LP | $466.10 | 2021-2023 | Farxiga |
| Mannkind Corporation | $437.40 | 2021-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $415.03 | 2021-2025 | |
| Dexcom, INC. | $338.18 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $324.45 | 2023-2025 | Freestyle Libre 3 |
| Amphastar Pharmaceuticals, INC. | $311.21 | 2023-2025 | Baqsimi |
| Antares Pharma, INC. | $296.80 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Medtronic, INC. | $258.04 | 2021-2024 | Minimed 780g, Inceptiv, Guardian Sensor (3) |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $249.31 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $218.45 | 2022-2025 | |
| Kyowa Kirin, INC. | $203.86 | 2023-2024 | Crysvita |
| Neurocrine Biosciences, INC. | $194.62 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $174.19 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $143.48 | 2021-2025 | |
| Ascendis Pharma Endocrinology INC | $141.06 | 2024-2025 | Yorvipath |
| Astellas Pharma US INC | $126.98 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $119.64 | 2021-2023 | |
| Amarin Pharma, INC. | $117.61 | 2021 | |
| Embecta Corp. | $115.63 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Corcept Therapeutics | $109.95 | 2021-2025 | Korlym |
| Cequr Corporation | $95.70 | 2022-2025 | Cequr Simplicity |
| Ultragenyx Pharmaceutical INC. | $92.93 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $92.34 | 2024-2025 | Strensiq |
| Merck Sharp & Dohme LLC | $91.93 | 2021-2022 | |
| Becton, Dickinson and Company | $82.00 | 2021-2022 | |
| Horizon Therapeutics Plc | $51.89 | 2023 | Tepezza |
| Amryt Pharma Holdings LTD | $50.44 | 2022 | |
| Averitas Pharma INC. | $48.39 | 2025 | Qutenza |
| Tolmar, INC. | $39.35 | 2023-2024 | |
| Eisai INC. | $36.23 | 2021 | |
| Bigfoot Biomedical INC | $29.74 | 2022 | |
| Ionis Pharmaceuticals, INC. | $25.97 | 2025 | Tryngolza |
| Zealand Pharma US, INC. | $24.36 | 2021 | |
| Intra-Sana Laboratories | $22.08 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Ibsa Pharma INC. | $20.24 | 2024 | Tirosint, Licart |
| Theracosbio, LLC | $16.37 | 2024 | Brenzavvy |
| Acella Pharmaceuticals, LLC | $15.69 | 2025 | NP Thyroid 60 |
| Shield Therapeutics INC | $15.52 | 2022 | |
| Beta Bionics, INC. | $14.50 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Takeda Pharmaceuticals U.S.A., INC. | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.